Genmab A/S (NASDAQ:GMAB) Stock Rating Upgraded by Truist Financial

Genmab A/S (NASDAQ:GMAB) was upgraded by research analysts at Truist Financial to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.

A number of other brokerages have also commented on GMAB. Wall Street Zen lowered Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Guggenheim decreased their target price on Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, February 23rd. Wells Fargo & Company began coverage on Genmab A/S in a report on Monday, March 2nd. They set an “overweight” rating and a $40.00 price target on the stock. HC Wainwright lifted their price target on shares of Genmab A/S from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Finally, Jefferies Financial Group began coverage on shares of Genmab A/S in a research note on Tuesday, February 17th. They issued a “buy” rating and a $41.50 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $40.58.

Genmab A/S Trading Up 1.2%

Shares of NASDAQ:GMAB opened at $26.11 on Wednesday. The stock has a market capitalization of $16.78 billion, a PE ratio of 16.85, a P/E/G ratio of 1.06 and a beta of 0.94. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $35.43. The firm has a fifty day moving average price of $29.68 and a 200 day moving average price of $30.50. The company has a current ratio of 2.02, a quick ratio of 2.01 and a debt-to-equity ratio of 0.86.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.46 by ($0.41). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. Analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

Hedge funds have recently added to or reduced their stakes in the business. Orbis Allan Gray Ltd increased its position in Genmab A/S by 30.2% in the 4th quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock worth $444,089,000 after buying an additional 3,340,456 shares during the period. Alliancebernstein L.P. boosted its position in shares of Genmab A/S by 2.7% in the third quarter. Alliancebernstein L.P. now owns 10,953,913 shares of the company’s stock valued at $335,957,000 after acquiring an additional 291,538 shares during the period. Paradigm Biocapital Advisors LP grew its stake in shares of Genmab A/S by 84.4% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,039,834 shares of the company’s stock worth $216,827,000 after acquiring an additional 3,222,983 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Genmab A/S by 36.6% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after purchasing an additional 1,334,919 shares during the period. Finally, Renaissance Technologies LLC grew its position in Genmab A/S by 23.8% in the 4th quarter. Renaissance Technologies LLC now owns 3,492,850 shares of the company’s stock worth $107,580,000 after purchasing an additional 671,307 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.